SLX-4090 is an orally active enterocytic-specific microsomal triglyceride transfer protein (MTP) inhibitor with an IC50 of 8.0 nM. SLX-4090 can be used for the research of dyslipidemia[1].
SLX-4090 inhibits apolipoprotein B (IC50 value 9.6 nM) but not apolipoprotein A1 secretion in Caco-2 cells[1].
SLX-4090 (orally, 30 mg/kg) reduces postprandial lipids by 50% with an ED50 value 7 mg/kg in rats[1].
[1]. Enoch Kim, et al. A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther. 2011 Jun;337(3):775-85.